EMEA-002760-PIP01-19 - paediatric investigation plan
rucaparib camsylate
PIPHuman
Hungarian is available via eTranslation, the European Commission's machine translation service.
Translate to Hungarian | Important information about machine translation
Key facts
- Invented name
- Rubraca
- Active substance
- rucaparib camsylate
- Therapeutic area
- Oncology
- Decision number
- P/0242/2020
- PIP number
- EMEA-002760-PIP01-19
- Pharmaceutical form(s)
- Film-coated tablet
- Condition(s) / indication(s)
- Treatment of fallopian tube cancer
- Treatment of ovarian cancer
- Treatment of primary peritoneal cancer
- Treatment of prostate malignant neoplasms
- Route(s) of administration
- Oral use
- Contact for public enquiries
Clovis Oncology Ireland Ltd
E-mail: regulatoryUK@clovisoncology.com
Tel. +44(0) 1223 645500- Decision type
- W: decision granting a waiver in all age groups for all conditions or indications
- Decision date
- Compliance check done
- Nem